Actively Recruiting
Accelerated Rotational Field Deep TMS for Treating OCD
Led by Ben-Gurion University of the Negev · Updated on 2025-08-12
50
Participants Needed
1
Research Sites
273 weeks
Total Duration
On this page
Sponsors
B
Ben-Gurion University of the Negev
Lead Sponsor
B
Brainsway
Collaborating Sponsor
AI-Summary
What this Trial Is About
A Prospective Double Blind Randomized Controlled Trial to Evaluate the Efficacy and Durability of the BrainsWay Rotational Field Deep Transcranial Magnetic Stimulation (Deep TMS) in Obsessive-Compulsive Subjects
CONDITIONS
Official Title
Accelerated Rotational Field Deep TMS for Treating OCD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Outpatients
- Diagnosed with OCD according to DSM-V
- Yale Brown Obsessive Compulsive Scale (YBOCS) score greater than 20
- Stable therapeutic dosage of serotonin reuptake inhibitors or other antidepressants/psychotropics for at least 2 months if on medication
- If undergoing cognitive behavioral therapy (CBT), must be in maintenance stage (not active exposure and response prevention) with at least ten sessions
- Negative or justified responses to Transcranial Magnetic Stimulation Safety Screening questionnaire
- Compliant with medication as assessed by treating physician if applicable
- Able and willing to provide informed consent and assent
- Willing and able to follow the treatment schedule
- All comorbid diagnoses stable for 3 months and expected to remain stable during treatment
You will not qualify if you...
- Primary diagnosis other than OCD (any other Axis I disorder)
- Unstable secondary psychiatric diagnoses likely needing treatment changes
- Present suicidal risk or history of suicide attempt in past year
- History of epilepsy or seizures except ECT-induced or febrile seizures in infancy
- Increased seizure risk due to conditions like raised intracranial pressure or significant head trauma with prolonged unconsciousness
- History of head injury requiring cranial surgery or prolonged coma
- Presence of ferromagnetic or conductive material in the head (including eyes and ears)
- Implanted neurostimulators, intracranial implants, or metallic eye particles
- Significant hearing loss
- Significant neurological disorders or insults
- Substance use disorder in past 6 months except nicotine and caffeine
- Participation in another therapeutic clinical study
- Unstable physical or metabolic disorders like unstable blood pressure, blood sugar, or cardiac disease
- Use of high-dose antidepressants or psychotropics known to lower seizure threshold, or current use of Clomipramine
- High risk of death within 18 months
- Planned surgeries interrupting study schedule within 4 months
- Breastfeeding, pregnant, or suspected pregnancy
- Women of childbearing potential not using medically accepted contraception when sexually active
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Soroka University Medical Center
Beersheba, Israel, 8410101
Actively Recruiting
Research Team
D
Dor Shukrun, PhD Student
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here